関連する実験動画

Updated: Feb 15, 2026

Quantifying Agonist Activity at G Protein-coupled Receptors

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

ヘテロメアグリシン受容体におけるドメイン結合の構造的基礎は,非典型のアロステルアゴニストによって明らかになった

Eric Gibbs¹, Bjarne Feddersen², Kayla J Kindig¹

¹Department of Pharmacology, Case Western Reserve University, Cleveland, OH 44106-4970, USA.

Science advances

|February 13, 2026

まとめ

グリシン受容体 (GlyR) ゲートへの構造的洞察は,イヴァルメクチンがこれらのチャネルを,ストレヒニンが存在する場合でも,異なるトランスメブランと細胞外領域のメカニズムを通じてどのように活性化するかを明らかにします.

科学分野:

神経科学は神経科学である.
構造生物学構造生物学とは
バイオケミストリーバイオケミストリー

背景:

グライシン受容体 (GlyRs) は,ペンタメリンのリガンドゲートイオンチャネル (pLGIC) の1種で,感覚および運動機能に不可欠です.
GlyRの機能状態は知られているが,これらの状態間の移行の構造的基礎は不明である.

研究の目的:

GlyRゲーティングとアロステリック変調の基礎となる構造的メカニズムを解明する.
超膜領域 (TMD) アゴニストと細胞外領域 (ECD) アゴニストの相互作用を調査する.

主な方法:

クリオ電子顕微鏡 (cryo-EM) で,ゲフィリンEドメインでGlyRα1β構造を決定する.
エレクトロフィジオロジーは,イヴァルメクチンとストリヒニンの存在におけるGlyR活性化を評価する.
リガンドの相互作用とドメインのダイナミクスを分析するための分子動力学 (MD) シミュレーション.

主要な成果:

構造は,閉じた状態と無感覚状態の間の無感性TMDとECDの適合性を持つ中間GlyR状態を明らかにしました.
イヴァルメクチンは,ストリヒニンが結合している場合でもGlyRを活性化させ,複雑なアロステル調節を示す.
MDシミュレーションでは,イヴァルメクチンがストリヒニンのダイナミクスを影響し,協調的なTMDアクティベーションメカニズムをサポートすることを示しました.

結論:

イバメクチンによるGlyR活性化には,協調的で対称的なTMDメカニズムが含まれています.
ECDのアロステリック変調は階層的で空間的に異質である.
これらの発見は,GlyRゲーティングとPLGICアロステリック調節の原理に関する新しい洞察を提供します.

さらに関連する動画

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Crystal Structure of the N-terminal Domain of Ryanodine Receptor from Plutella xylostella

Crystal Structure of the N-terminal Domain of Ryanodine Receptor from Plutella xylostella

Published on: November 30, 2018

関連する概念動画

G-protein Coupled Receptors

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Drug-Receptor Interaction: Agonist

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...

G Protein-coupled Receptors

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...

Cooperative Allosteric Transitions

Cooperative Allosteric Transitions

Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...

Conservation of Protein Domains Over Different Proteins

Conservation of Protein Domains Over Different Proteins

Protein domains are small structurally independent units that are part of a single amino acid chain. Although these domains are often structurally independent, they may rely on synergistic effects to perform their functions as part of a larger protein. Protein domains may be conserved within the same organism, as well as across different organisms.
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...